CIC
SUPN icon

Cornercap Investment Counsel’s Supernus Pharmaceuticals SUPN Stock Holding History

Cornercap Investment Counsel’s Portfolio SUPN Stock Details SUPN Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2020
Q4 		– Sell
-20,580
Closed -$429K – 596
2020
Q3 		$429K Sell
20,580
-16,349
-44% -$371K 0.06% 419
2020
Q2 		$877K Buy
+36,929
New +$816K 0.14% 257
2018
Q2 		– Sell
-17,535
Closed -$803K – 452
2018
Q1 		$803K Buy
+17,535
New +$732K 0.11% 211

Other funds holding SUPN

BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
AC
Armistice Capital New York $5.62B AUM 36.06% 1-Year Est. Return
Macquarie Group
Macquarie Group Sydney, NSW 2000, Australia $16.8B AUM 27.39% 1-Year Est. Return
Dimensional Fund Advisors
Dimensional Fund Advisors Austin, Texas $481B AUM 30.42% 1-Year Est. Return
Renaissance Technologies
Renaissance Technologies New York $63.9B AUM 45.56% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return
GKIM
GW&K Investment Management Boston, Massachusetts $11.3B AUM 31.98% 1-Year Est. Return
Fuller & Thaler Asset Management
Fuller & Thaler Asset Management San Mateo, California $29.7B AUM 43.33% 1-Year Est. Return
ACM
Ashford Capital Management Wilmington, Delaware $809M AUM 35.1% 1-Year Est. Return

Cornercap Investment Counsel's SUPN Position: Q4 2020 in Review

Cornercap Investment Counsel sold out of Supernus Pharmaceuticals (SUPN) in Q4 2020, closing a stake of 20,580 shares — an estimated $429K sold.

Cornercap Investment Counsel first reported a position in SUPN in Q1 2018 and held it in 3 quarters. The position peaked at $877K in Q2 2020. 225 funds tracked by Wall St. Rank hold SUPN as of Q4 2020.

  • Cornercap Investment Counsel reported no remaining Supernus Pharmaceuticals position as of Q4 2020 after selling out during the quarter.
  • Cornercap Investment Counsel sold 20,580 Supernus Pharmaceuticals shares in Q4 2020, an estimated $429K.
  • Cornercap Investment Counsel first reported a position in Supernus Pharmaceuticals in Q1 2018 and held it in 3 quarters.
  • Cornercap Investment Counsel's Supernus Pharmaceuticals position peaked at $877K in Q2 2020.
  • 225 funds tracked by Wall St. Rank held Supernus Pharmaceuticals as of Q4 2020.

Based on Cornercap Investment Counsel's 13F filing for Q4 2020, filed 16 Feb 2021.